SGN-40: Phase I update data

Updated data from an open-label, dose-escalation, U.S. Phase I trial in 13 patients showed that repeated infusions of SGN-40 at doses of 0.5, 1 and 2 mg/kg were well tolerated. At 4 mg/kg, 2 of 3 pati...